158 related articles for article (PubMed ID: 31729149)
1. Cancer immunotherapy trial design with delayed treatment effect.
Wu J; Wei J
Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
Wei J; Wu J
Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
[TBL] [Abstract][Full Text] [Related]
3. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
Wu J; Li Y; Zhu L
J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
[TBL] [Abstract][Full Text] [Related]
4. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Xiong X; Wu J
Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
[TBL] [Abstract][Full Text] [Related]
5. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
Ding X; Wu J
Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
[TBL] [Abstract][Full Text] [Related]
6. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
7. A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect.
Li B; Su L; Gao J; Jiang L; Yan F
Stat Methods Med Res; 2021 Mar; 30(3):904-915. PubMed ID: 33357047
[TBL] [Abstract][Full Text] [Related]
8. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
Wang Z; Zhang Q; Xue A; Whitmore J
Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
Wu J; Wei J
Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
[TBL] [Abstract][Full Text] [Related]
10. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chu C; Liu S; Rong A
Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
[TBL] [Abstract][Full Text] [Related]
11. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial design with growth modulation index as the primary endpoint.
Wu J; Chen L; Wei J; Weiss H; Miller RW; Villano JL
Pharm Stat; 2019 Mar; 18(2):212-222. PubMed ID: 30458583
[TBL] [Abstract][Full Text] [Related]
13. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy trial design with long-term survivors.
Ding X; Wu J
Pharm Stat; 2021 Jan; 20(1):117-128. PubMed ID: 32869945
[TBL] [Abstract][Full Text] [Related]
15. Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.
Shan G
J Biopharm Stat; 2020 Sep; 30(5):797-805. PubMed ID: 32129130
[TBL] [Abstract][Full Text] [Related]
16. Group sequential multi-arm multi-stage survival trial design with treatment selection.
Wu J; Li Y
J Biopharm Stat; 2024 Jul; 34(4):453-468. PubMed ID: 37455424
[TBL] [Abstract][Full Text] [Related]
17. Two-stage phase II survival trial design.
Wu J; Chen L; Wei J; Weiss H; Chauhan A
Pharm Stat; 2020 May; 19(3):214-229. PubMed ID: 31749311
[TBL] [Abstract][Full Text] [Related]
18. Design and analysis of clinical trials in the presence of delayed treatment effect.
Sit T; Liu M; Shnaidman M; Ying Z
Stat Med; 2016 May; 35(11):1774-9. PubMed ID: 26833957
[TBL] [Abstract][Full Text] [Related]
19. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
Ye T; Yu M
Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
[TBL] [Abstract][Full Text] [Related]
20. Statistical and practical considerations in designing of immuno-oncology trials.
Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
